A prospective study to explore whether IgG autoantibodies directed against co-expressed antigens by tumor tissue and healthy skin correlate with skin immune related adverse events and therapy outcome
Latest Information Update: 04 Sep 2019
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Most Recent Events
- 04 Sep 2019 New trial record
- 23 Aug 2019 Results published in the Journal of the American Academy of Dermatology.